Shelley Chu

SFJ Pharmaceuticals, Inc. develops pharmaceuticals drugs. It offers drugs for cancer, kidney, thyroid, leukemia, and lung cancer. The company was founded by Roberto DeBenedetto in January 2009 and is headquartered in Pleasanton, CA.

Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA.

3T Biosciences, Inc. operates as immunotherapy company. The company was founded by Luke J. Lee, Marvin Gee and Leah Sibener and is headquartered in Palo Alto, CA.

Novartis Inflammasome Research, Inc. operates as a biopharmaceutical company, which engages in the development of a suite of NOD-, LRR- and pyrin domain-containing 3 (NLRP3) antagonists for the treatment of inflammatory diseases. It also develops chemically distinct systemic, gut-directed, and central nervous system (CNS)-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurological diseases. The company was founded by Eicke Latz and Luigi Franchi in 2017 and is headquartered in Boston, MA.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Adanate, Inc. develops antibody therapeutics. The CEO of the American company is Chris Griffith.

Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA.

Protego Biopharma operates as a biotechnology firm. The company is headquartered in San Diego, CA.

IFM Cinque, Inc. is a biotechnology company. The company is headquartered in Boston, MA.

IFM Continua, Inc. engages in the provision of biotechnology services. The company is headquartered in Boston, MA.

IFM Quattro, Inc. is a biotechnology company. The company is headquartered in Boston, MA.

Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA.

Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA.

Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016.

Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021.

Enlaza Therapeutics, Inc. is a company that develops novel classes of protein therapeutics using their proprietary war-lock™ platform. The company is based in La Jolla, CA. The company's platform utilizes synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza Therapeutics is pioneering the field of covalent biologics and aims to deliver more efficacious and safer treatments for patients. The CEO of the company is Sergio G. Duron.

Ifm Therapeutics, Inc. develops immunotherapy that focuses on targeting the adaptive immune system. The private company is based in Boston and was founded by Jean-Francois B. Formela.

Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer.

Seismic Therapeutic, Inc. is a biotechnology company located in the biotechnology hub. The American company is making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. Seismic Therapeutic has a growing preclinical stage and first-in-class biologics pipeline, derived from its integrated impact platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company was founded by Joanne Viney, Alan L. Crane, and Joanne Viney has been the CEO since incorporation.